Table 3. Studies reporting outcomes of metastatic biliary tract cancer patients treated with FOLFIRI.
| 1st author year | Regimen | N | Design | Line | ORR | mPFS | mOS |
|---|---|---|---|---|---|---|---|
|
Feisthammel30 2007 |
FOLFIRI | 30 | Single-arm PHASE II | 1st | 10% | 2.8 m (intrahepatic) 5.2 m (extrahepatic) |
5.4 m (intrahepatic) 9 m (extrahepatic) |
|
Brieau16 2015 |
FOLFIRI | 64 b | Retrospective | 2nd | 11.5% | 2.6 m | 6.1 m |
|
Moretto17 2013 |
FOLFIRI | 24 b 30 p |
Retrospective | 38% 2nd | 42.9% (CBR) | 3.5 m | 6.2 m |
|
Sebbagh18 2015 |
FOLFIRI | 52 | Retrospective | 2nd | N/A | 3.2 m | 8.4 m |
|
Mizrahi31 2019 |
FOLFIRI | 98 | Retrospective | 2nd and beyond | 11% | 2.4 m | 6.6 m |
|
Caparica 2019 |
FOLFIRI | 12 | Retrospective | 2nd and beyond | 17% (CBR) |
1.7 m | 5 m |
b = biliary; CBR = clinical benefit rate; m = months; mPFS = median progression-free survival; mOS = median overall survival; N = number of patients; ORR = overall response rate; p = pancreatic; N/A = not available.